<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=192888919167017&amp;ev=PageView&amp;noscript=1">
Sunday,  July 21 , 2024

Linkedin Pinterest
News / Business

Sliding stocks harsh cannabis buzz

Stalled mergers, government rules weigh on industry

By ALEX VEIGA, Associated Press
Published: December 7, 2019, 6:00am

LOS ANGELES — When it comes to investing in cannabis stocks, the marijuana bud’s faded bloom has shown few signs of returning this year.

Cannabis stocks have had a harsh comedown as investors’ enthusiasm about the prospects for strong growth and blockbuster company mergers has dimmed.

The ETFMG Alternative Harvest exchange traded fund, which focuses on cannabis stocks, is down 32.5 percent this year and off 40.1 percent from a year ago. Shares in some of the biggest marijuana companies, including Tilary, MedMen Enterprises and Aurora Cannabis, have fallen much further.

At the same time, the broader stock market is on track for strong gains. The S&P 500 index is up 25.5 percent this year and 16.7 percent above where it stood 12 months ago.

Demand hasn’t been an issue for companies that sell marijuana products in U.S. states where cannabis is legal in some form. What’s been weighing on stocks is a stalled wave of big company mergers that many investors were banking on to drive shares higher.

The Department of Justice is still reviewing several proposed deals that were announced late last year and early this year for possible antitrust concerns.

Two companies involved in one of those mergers said last month that they had entered a 30-day waiting period after complying with a request for more information on the deal from the Department of Justice. That raised the possibility that regulators could be close to wrapping up their review of the deal, which was valued at the time of the announcement in April at $850 million.

The uncertain fate of that and other proposed mergers has put a chill on more deals this year.

In October, Los Angeles-based MedMen Enterprises backed out of its attempt to buy PharmaCann, a Chicago-based marijuana company. At the time, MedMen noted that the pullback in U.S. and Canadian cannabis stocks, which makes it tougher for public companies to raise money from stock sales, made it increasingly critical to allocate capital efficiently.

“A lack of access to capital has been a main issue this year in the U.S.,” said Canaccord Genuity analyst Bobby Burleson. “When we get some sizable deals closing, that will be a positive catalyst for the U.S. players.”

Government regulations remain hurdles for companies in the business of growing, distributing or selling cannabis.

A U.S. House committee approved a proposal to decriminalize and tax marijuana at the federal level last month. The news only gave pot stocks a momentary bump. It’s unclear whether the measure will be taken up in the GOP-controlled Senate.

Vaping-related deaths and illnesses have also hurt cannabis stocks, though recent data suggest the scare dampened sales mainly in California, where vaping products make up a larger share of overall sales.

Still, industry analysts project the market for marijuana products will continue to grow over the next decade, which should bode well for cannabis stocks.

Burleson expects cannabis retail sales in legal U.S. state markets will climb from an estimated $12.9 billion this year to $31.3 billion in 2024.